Name (Synonyms) | Correlation | |
---|---|---|
drug105 | Abivertinib Wiki | 1.00 |
drug2319 | Standard of Care Wiki | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.11 |
D055371 | Acute Lung Injury NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.10 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.
Description: VFD for 28 days after administration of the investigational product
Measure: Ventilator-free days (VFD)(ARDS caused by pneumonia cohort) Time: 28 days after administration of the investigational productDescription: The number and rate of adverse events
Measure: Adverse events(ARDS caused by COVID-19 cohort) Time: From informed consent to 180 days after administration of the investigational productDescription: Change from baseline in systolic blood pressure(mmHg)
Measure: Change from baseline in systolic blood pressure(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in diastolic blood pressure(mmHg)
Measure: Change from baseline in diastolic blood pressure(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in pulse rate(beats/min)
Measure: Change from baseline in pulse rate(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in respiration(breath/min)
Measure: Change from baseline in respiration(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in oxygen saturation(%)
Measure: Change from baseline in oxygen saturation(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in body temperature(C)
Measure: Change from baseline in body temperature(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in red blood cell count(/uL)
Measure: Change from baseline in red blood cell count(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in hemoglobin(g/dL)
Measure: Change from baseline in hemoglobin(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in hematocrit(%)
Measure: Change from baseline in hematocrit(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in leukocyte count(/uL)
Measure: Change from baseline in leukocyte count(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in neutrophils(%)
Measure: Change from baseline in neutrophils(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in eosinophils(%)
Measure: Change from baseline in eosinophils(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in basophils(%)
Measure: Change from baseline in basophils(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in lymphocytes(%)
Measure: Change from baseline in lymphocytes(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in monocytes(%)
Measure: Change from baseline in monocytes(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in platelet count(/uL)
Measure: Change from baseline in platelet count(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in asparate aminotransferase(AST)(IU/L)
Measure: Change from baseline in asparate aminotransferase(AST)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in alanine aminotransferase(ALT)(IU/L)
Measure: Change from baseline in alanine aminotransferase(ALT)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in alkaline phosphatase(ALP)(IU/L)
Measure: Change from baseline in alkaline phosphatase(ALP)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in total bilirubin(mg/dL)
Measure: Change from baseline in total bilirubin(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in blood urea nitrogen(BUN)(mg/dL)
Measure: Change from baseline in blood urea nitrogen(BUN)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in creatinine(mg/dL)
Measure: Change from baseline in creatinine(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in sodium(Na)(mmol/L)
Measure: Change from baseline in sodium(Na)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in potassium(K)(mmol/L)
Measure: Change from baseline in potassium(K)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in chloride(Cl)(mmol/L)
Measure: Change from baseline in chloride(Cl)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in calcium(Ca)(mg/dL)
Measure: Change from baseline in calcium(Ca)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in blood sugar(mg/dL)
Measure: Change from baseline in blood sugar(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in urinary protein(- to >= 4+)
Measure: Change from baseline in urinary protein(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in urinary sugar(- to >= 4+)
Measure: Change from baseline in urinary sugar(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in uric blood(- to >= 4+)
Measure: Change from baseline in uric blood(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in urinary sediment(RBC)(/HPF)
Measure: Change from baseline in urinary sediment(RBC)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in urinary sediment(WBC)(/HPF)
Measure: Change from baseline in urinary sediment(WBC)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational productDescription: Change from baseline in urinary sediment(Other)(/HPF)
Measure: Change from baseline in urinary sediment(Other)(ARDS caused by COVID-19 cohort) Time: From screening to 180 days after administration of the investigational product